Lead Product(s) : Rolapitant HCl
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Tesaro
Deal Size : Inapplicable
Deal Type : Inapplicable
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms, Germ Cell and Embryonal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 22, 2019
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Tesaro
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 05, 2015
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 09, 2015
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 07, 2014
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 28, 2011
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 28, 2011
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 26, 2011
Lead Product(s) : Rolapitant HCl
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
